EGFR and non-small cell lung carcinoma: From pre-clinical data and the CHRYSALIS clinical trial, it is clear that amivantamab has activity against multiple distinct EGFR exon 20 insertions and, coupled with a tolerable safety profile, provides a viable therapeutic option for NSCLC patients who fail to respond to standard of care chemotherapy.